Cupid Limited Publishes Audited FY26 Financial Results in Newspapers
Cupid Limited published newspaper clippings of its audited financial results for Q4 and FY26 in Business Standard and Maharashtra Times on May 16, 2026, per SEBI Regulation 33. The company reported a sharp rise in Q4 net profit to 362M rupees from 116M rupees YoY, with EBITDA margin expanding to 38.6% from 23.81%, and full-year standalone profit after tax at 640.42M rupees on total income from operations of 6,651.38M rupees.

*this image is generated using AI for illustrative purposes only.
Cupid Limited reported strong standalone financial results for the fourth quarter and financial year ended March 31, 2026, with net profit rising sharply to 362M rupees compared to 116M rupees in the same period of the previous year. Revenue for the quarter came in at 1.2B rupees, against 565M rupees in the corresponding period last year, reflecting robust year-on-year growth across key financial parameters. In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company subsequently published newspaper clippings of its audited financial results in Business Standard (English) and Maharashtra Times (Marathi) dated May 16, 2026.
Financial Performance
The company's quarterly performance demonstrated significant improvement across profitability and operational metrics. EBITDA for the quarter stood at 463M rupees, compared to 135M rupees in the year-ago period, while EBITDA margin expanded meaningfully to 38.6% from 23.81% in the same quarter last year. The following table summarizes Cupid's key standalone financial metrics for the quarter:
| Metric: | Q4 Current Period | Q4 Previous Year (YoY) |
|---|---|---|
| Net Profit | 362M rupees | 116M rupees |
| Revenue | 1.2B rupees | 565M rupees |
| EBITDA | 463M rupees | 135M rupees |
| EBITDA Margin | 38.6% | 23.81% |
The sharp expansion in EBITDA margin — from 23.81% to 38.6% year-on-year — underscores the company's improved cost management and stronger operating leverage. The full-year standalone profit after tax was recorded at 640.42M rupees, with total income from operations at 6,651.38M rupees for the financial year ended March 31, 2026.
Regulatory Disclosure
The Board of Directors approved the audited financial results at a meeting held on May 15, 2026. Following the board approval, Cupid filed the requisite newspaper clippings with BSE Limited and the National Stock Exchange of India Ltd. on May 16, 2026, as mandated under Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The submission was signed by Hardik Chandra, Company Secretary and Compliance Officer. The detailed results, along with the Auditor's Report, have been posted on the company's website at https://www.cupidlimited.com/financial-reports/ .
Publication Details
The following table outlines the key details of the newspaper publication:
| Parameter: | Details |
|---|---|
| Newspapers Published In | Business Standard (English), Maharashtra Times (Marathi) |
| Date of Publication | May 16, 2026 |
| Board Approval Date | May 15, 2026 |
| Period Covered | Quarter and Financial Year ended March 31, 2026 |
| Regulatory Compliance | Regulation 33 read with Regulation 47(1), SEBI LODR Regulations, 2015 |
| Registered Office | A-68, M.I.D.C. (Malegaon), Sinnar, Nashik – 422113, Maharashtra, India |
Cupid Limited is a manufacturer and exporter of male condoms, female condoms, water-based lubricants, and In Vitro Diagnostics (IVD) kits, operating from its registered and factory office in Nashik, Maharashtra.
Source: None/Company/INE509F01029/79c8ac2878fb4be6.pdf
Historical Stock Returns for Cupid
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.91% | +12.99% | +9.21% | +91.92% | +610.13% | +6,353.98% |
Can Cupid Limited sustain its 38.6% EBITDA margin in upcoming quarters, or were there one-time factors driving the margin expansion in Q4 FY2026?
How is Cupid Limited positioned to capitalize on growing global demand for sexual health and IVD products, particularly in export markets?
Will the strong FY2026 earnings performance lead to increased dividend payouts or capital allocation toward capacity expansion?


































